ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to
abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.
This Phase 3B trial was designed to evaluate the efficacy and safety of VIVITROL versus
placebo. Injections were administered to patients in whom abstinence was enforced by a period
of inpatient hospitalization of 7 to 21 days.